FDA Inspection 1238621 — Zhejiang Hisun Pharmaceutical Co., Ltd.
The FDA completed an inspection of Zhejiang Hisun Pharmaceutical Co., Ltd. on June 21, 2024 in Taizhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- June 21, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Taizhou (China)